Lightnix decided to participate as a partner company in i2.JP led by AstraZeneca
SOKA, Japan--(BUSINESS WIRE)--Dec 25, 2022--
Lightnix Inc. (2-3-9 Takasago, Soka-shi, Saitama Prefecture; CEO: Shosuke Kiba) has decided to participate as a partner company in “Innovation Infusion Japan” (“i2.JP”; Website: https://www.i2jp.net/en/index.html ), an initiative sponsored by AstraZeneca K.K. (Kita-ku, Osaka-shi, Osaka Prefecture; President: Takafumi Horii).
i2.JP is a new initiative that promotes open innovations in the healthcare field. Its goal is to contribute to next-generation healthcare through partnerships with companies, academia, and government.
Lightnix seeks to create innovations in healthcare through the development of intradermal vaccine injection devices and other new drug delivery methods.
By leveraging its strengths in this field, the company aims to resolve healthcare issues related to vaccine and drug delivery in partnership with both the public and private sectors, including the healthcare sector and industries worldwide participating in i2.JP.
View source version on businesswire.com:https://www.businesswire.com/news/home/20221222005584/en/
CONTACT: Lightnix Inc.
Akihiro ISUMI, General Manager
KEYWORD: JAPAN ASIA PACIFIC
INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH MEDICAL DEVICES
SOURCE: Lightnix Inc.
Copyright Business Wire 2022.
PUB: 12/25/2022 08:30 PM/DISC: 12/25/2022 08:31 PM